Readnour Robin Shane's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Nov 21, 2024
- Accession no.
- 0000950170-24-129830
- Filed
- Nov 21, 2024
- Trade date
- Nov 19-20, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $213.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Readnour Robin ShaneCIK 0001914883 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 | Common Stock | PPurchaseAcquired | +75,000 | $1.03 | +$77,250 | 560,073 | Indirect | |
| Nov 19, 2024 | Common Stock | PPurchaseAcquired | +75,000 | $1.04 | +$78,000 | 489,788 | Indirect | |
| Nov 20, 2024 | Common Stock | PPurchaseAcquired | +25,000 | $1.16 | +$29,000 | 585,073 | Indirect | |
| Nov 20, 2024 | Common Stock | PPurchaseAcquired | +25,000 | $1.15 | +$28,750 | 514,788 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.